Phosphodiesterase 9 inhibition prolongs the antiparkinsonian action of l-DOPA in parkinsonian non-human primates

Phosphodiesterase 9 (PDE9) degrades selectively the second messenger cGMP, which is an important molecule of dopamine signaling pathways in striatal projection neurons (SPNs). In this study, we assessed the effects of a selective PDE9 inhibitor (PDE9i) in the primate model of Parkinson's diseas...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Neuropharmacology 2022-07, Vol.212, p.109060, Article 109060
Hauptverfasser:	Masilamoni, Gunasingh J., Sinon, Christopher G., Kochoian, Brik A., Singh, Arun, McRiner, Andrew J., Leventhal, Liza, Papa, Stella M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antiparkinson Agents - pharmacology Antiparkinson Agents - therapeutic use Antiparkinsonian Cyclic nucleotides Disabled Persons Disease Models, Animal Dopamine Dyskinesia, Drug-Induced - drug therapy Humans l-DOPA induced Dyskinesia Levodopa - therapeutic use Motor Disorders - drug therapy MPTP Parkinson Disease - drug therapy Parkinson's disease PDE9 inhibitor Phosphoric Diester Hydrolases Primates
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!